Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2021-12-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including the cancellation of options for specific individuals. This type of filing, which concerns changes to capital structure and employee compensation instruments, is classified as a regulatory filing regarding share-related matters. Given the specific nature of stock option grants and their impact on capital, it falls under the 'RNS' (Regulatory Filings) category as it is a formal disclosure to the financial authorities (Financial Services Commission/Korea Exchange).
2021-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including cancellations and adjustments to the total number of options. In the context of financial filings, reports regarding stock option grants, amendments, or capital changes that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) are classified as general regulatory filings.
2021-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details a correction (정정신고) to a previously filed stock option grant, specifically updating the number of recipients and the total number of shares granted due to employee departures. This type of filing relates to capital structure and share-based compensation, which falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by financial authorities.
2021-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including the cancellation of options for a specific individual. This type of disclosure regarding equity compensation and changes to capital structure/incentives falls under the category of regulatory filings for corporate actions that do not fit into specific financial reporting categories like 10-K or Earnings Releases.
2021-12-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically marked as a '정정신고' (Amendment Report). It details changes to the number of shares and exercise price of stock options previously granted. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Remuneration Information' (which is typically for executive compensation disclosures in proxy statements).
2021-12-30 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and the closure of the shareholder register for the purpose of holding an Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notice of the upcoming meeting logistics. Given it is a standard regulatory announcement regarding corporate governance and meeting preparation, it falls under the RNS category.
2021-12-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.